$27.95−0.13 (−0.45%)
Market open · 15-min delayed · as of 1:23 PM ET
Amylyx Pharmaceuticals Inc · Statistics
Cheap or expensive, strong or fragile. Every ratio ranked against its sector peers — the number we score — with its own ten-year record shown beside it for context.
VALUE
Rich vs sector
premium price vs peers
QUALITY
Weak
below-peer returns
HEALTH
Sturdy
leverage data unavailable; scored on the rest
GROWTH
No data
insufficient peers
In one line
A weak business at a rich price for its sector: value 16, quality 19, health 84, each a percentile within Healthcare.
On October 2, 2026 the Tenet Score and these statistics moved from the latest fiscal year to the trailing twelve months, for companies that file quarterly statements. Scores before October 2, 2026 were computed on fiscal-year figures.
Values are the trailing twelve months where a company files quarterly statements and the figure passes our check against the filings, with balance-sheet ratios from the most recent quarter; otherwise, or where a sector's figure is still under review, the latest fiscal year. Piotroski and the five-year growth rates are fiscal years. Each row names its period.track = where peers land, worse → better (direction-adjusted: right always means better)▏sector median● you are here▲ where today's value sits in the company's own ten fiscal years (context, not scored)hover any metric for its formula
Valuation
16th pctilepremium price vs peersEBIT (operating income) for the latest fiscal year ÷ enterprise value on the current market cap (Greenblatt). The vendor's own earnings yield is net income to common ÷ market cap, a different figure.—excluded: no value on file for this company
Financial health
84th pctileleverage data unavailable; scored on the restMost recent quarter: (Cash, short-term investments and receivables) ÷ current liabilities on the most recent quarter's balance sheet, as the data vendor builds it for that quarter. Its receivables include non-trade receivables, which Tenet's balance sheet shows inside other current assets.11.8684th pctileMost recent quarter, Jun 30, 2026
(Total debt − cash) ÷ EBITDA—excluded: negative EBITDA denominator
Profitability & returns
19th pctilebelow-peer returnsAltman's bankruptcy-distance score for the latest fiscal year, with its market-value term at the fiscal year end; higher is safer, as the data vendor publishes it (vendor definition, not reproduced).—excluded: no value on file for this company
Growth
insufficient peers★ Corrected metrics: why we compute these ourselves
the receipts behind the numbers aboveGreenblatt earnings yield—EBIT ÷ EV The vendor's "earningsYield" is NI ÷ market cap, which is not Greenblatt's formula.
ROIC−68%NOPAT ÷ invested capital The vendor's simple ROIC, not its tiny-base roic tag; withheld when a negative EBIT flips its sign.
Interest coverage— Guarded, not faked: we have no interest-expense figure on file for this company, so it's excluded from the ranking instead of rendered as garbage.
Every raw line behind these ratios→
All three statements: 5 years free, 10 on Premium, 20 on Ultimate
Quarterly, in fiscal years: 1 free, 5 on Premium, Unlimited on Ultimate
These percentiles feed the value, income, timing and long-hold tenets→
See which criteria pass, with the live number and the rule behind each
Percentiles computed nightly against 400 Healthcare peers from our ingested fundamentals DB · raw statements for corrected metrics. Direction-adjusted: for "lower is better" ratios (P/E, D/E…) the percentile is flipped so right always means better. The percentile is the stock's rank among sector peers, the number that is scored. The triangle marks where the current value (the trailing twelve months or the latest fiscal year, as its row names) sits in the company's own ten fiscal-year record, shown for context and never blended into the score. Computed 2026-10-02 · Not investment advice.